DAMON RUNYON CANCER RESEARCH FOUNDATION FELLOWSHIP AWARD
The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Candidates must apply for the fellowship under the guidance of a Sponsor – a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow.
Damon Runyon Fellowship Award Application Guidelines
Overview | Application Deadlines | Application Requirements
A recording of the Fellowship Informational Session from February 1, 2024 is available here.
Application opens on Proposal Central: June 15, 2025
Application due on or before: August 15, 2025
NC TRACS TIPS FOR PREPARING A SUCCESSFUL PCORI PROPOSAL
Join NC TraCS on April 9 from 2 – 3 p.m. for a hybrid session introducing PCORI—the Patient Centered Outcomes Research Institute. Learn more about PCORI, its goals and funding mechanisms, as well as tips and strategies for preparing a competitive PCORI proposal. REGISTER
Limited Submission Internal Call for Proposals
THE BRAIN RESEARCH FOUNDATION 2026 SCIENTIFIC INNOVATIONS AWARD provides funding for innovative science in basic and clinical neuroscience. The program supports creative, exploratory, cutting-edge research in well-established research laboratories, under the direction of established investigators (associate or full professors) working in the area of neuroscience and brain function in health and disease (please see details below).
Budget: $150,000 (direct costs) for a two-year grant period.
UNC Internal Deadline: 11:59 PM, Monday, April 28, 2025
Brain Research Foundation LOI Deadline: June 3, 2025
Brain Research Foundation Phase II Deadline (Invitation only): September 23, 2025
PhRMA FOUNDATION WEBINAR RECORDING: 2026 Funding Opportunities Informational Session
Watch this webinar recording for insights into the application process, tips for applying, and free resources on grant writing. WATCH NOW
PhRMA FOUNDATION RESEARCH FUNDING OPPORTUNITIES in Drug Discovery, Drug Delivery, and Translational Medicine
Predocs: $30K a year for 2 years
Postdocs: $60K a year for 2 years
New Faculty: $100K for 1 year
Letters of Intent Deadline: April 15, 2025 at 12 PM ET
The application portal is now open for PhRMA Foundation grants and fellowships in Drug Discovery, Drug Delivery, and Translational Medicine. Letters of Intent are due on April 15, 2025 at 12 PM ET
The Horizon Europe MARIE SKŁODOWSKA-CURIE ACTIONS POSTDOCTORAL FELLOWSHIP call 2025 opens soon, with the deadline 10th September 2025. This program supports postdoctoral trainees who wish to acquire new skills in Europe and elsewhere through advanced training. The fellowship offers 12-24 months full-time research funding. Queen’s University Belfast, including the School of Pharmacy, is accepting applications through this program.
Explore the list of supervisors at QUB who would like to host a fellow. Please directly email the supervisor you are interested in working with, enclosing your CV and providing a short abstract of your proposed project (including background to the project, objectives and approach). Once it is agreed that the application will proceed, our team will schedule a call to discuss your application and agree a timeline for the preparation of your application. Our team will assist you and your chosen Queen’s host by providing guidance and review throughout the preparation of your application. The deadline for contact with a host is 30th April 2025.
Faculty at QUB SOP who are interested in accepting applications through this program include:
| Name | Areas of research interest | Pure profile | |
| Tim Skvortsov | Phage biology, phage synthetics biology, microbial bioinformatics | https://pure.qub.ac.uk/en/persons/tim-skvortsov | t.skvortsov@qub.ac.uk |
| Dimitrios Lamprou | 4D Printing, Bioprinting, Microfluidics, Lab-on-a-chip, Pharmaceutics | https://pure.qub.ac.uk/en/persons/dimitrios-lamprou | D.Lamprou@qub.ac.uk |
| Garry Laverty | Drug delivery, biomaterials, pharmaceutical microbiology, medicinal chemistry, peptide science | https://pure.qub.ac.uk/en/persons/garry-laverty | Garry.laverty@qub.ac.uk |
| Emma McErlean – visited ESOP in February 2025 | https://pure.qub.ac.uk/en/persons/emma-dynes | E.McErlean@qub.ac.uk | |
| Jonathan Coulter – visited ESOP in February 2025 | https://pure.qub.ac.uk/en/persons/jonathan-coulter | j.coulter@qub.ac.uk | |
This program supports applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. Multidisciplinary research teams must have a highly integrated approach for each of their project goals. The program is designed to support research in which funding a team of interdependent investigators to achieve a unified scientific goal offers significant advantages over supporting individual research project grants.
NIGMS supports generalizable, foundational basic research that increases understanding of biological processes at a range of levels, from molecules and cells, to tissues, whole organisms, and populations. NIGMS also supports research in a limited number of clinical areas that affect multiple organ systems.
UNC Internal Deadline: 11:59 PM, Monday, March 31, 2025
LOI Due Date: April 28, 2025
NIH Application Deadline: May 28, 2025
Number of Applications per Institution: Two
Budget: While applications may request research program budgets of up to $1.5 million direct costs per year, it is anticipated that most awards will be between $700,000-$900,000 direct costs. An additional $250,000 direct costs per year may be requested for optional developmental funds to support the addition of early-stage investigators (ESIs) to the program in years 2-5.
Project Period: Up to 5 years
NC TRACS CLINICAL AND TRANSLATIONAL SCIENCE PILOT PROJECTS
The NC TraCS Clinical and Translational Science (CTS) Pilot Program is seeking proposals that focus on understanding a scientific or operational principle underlying a step of the translational research process with the goal of developing generalizable principles to accelerate translation. Projects must be feasible within a one-year time frame and have high scientific and methodological quality.
Funding: For each annual CTS pilot grant cycle, NC TraCS will award up to eight (8) grants of $25,000 – $50,000 direct costs. Awards are to be expended within a 12-month period starting from the date of issue of a Notice of Award. Budget details and procedures, including allowed expenses, are detailed in the Application Instructions (UPDATED: RFA version released 3/1/25).
Prospective applicants are required to meet with Pilot Program staff to discuss their project prior to submission. Staff can advise on how to best present the translational science problem to be addressed, the general methodological approach, and whether any NC TraCS services might be useful to the project. Applications are due July 8.
BIOENGINEERING RESEARCH GRANTS (R01 CLINICAL TRIAL NOT ALLOWED) PAR-22-242
The funding program encourages collaborations between life science and physical science that:
- apply a multidisciplinary bioengineering approach to solve biomedical problems; and
- develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques that: (a) fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, (b) are capable of enhancing our understanding of health and disease, and/or (c) improve practice of medicine.
Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.
Examples of technologies include, but not limited to:
- Synthetic biology devices to advance understanding of cancer biology
- Nanotechnologies capable of biological discovery
- Engineered biomaterials physiologically-relevant to tumors
- Biomimetic cell/tissue culture systems and organoids for testing delivery systems
- Therapeutics & implants that could improve treatment and healthcare
Application Deadline: June 05, 2025
DAMON RUNYON CANCER RESEARCH FOUNDATION
BIOENGINEERING PARTNERSHIPS WITH INDUSTRY (U01 CLINICAL TRIAL OPTIONAL) (PAR-24-325)
This RFA solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years.
Award Budget: Not limited but should reflect needs of proposed project
Award Project Period: Maximum 5 years
Application deadlines:
May 28, 2025
January 27, 2026
May 27, 2026
January 27, 2027
May 27, 2027
Letter of Intent Due Date: 30 days prior to the application due date
ALZHEIMER’S DRUG-DEVELOPMENT PROGRAM (U01 CLINICAL TRIAL OPTIONAL) – (PAR-25-297)
The overarching goal of the program is the development of a broad range of novel drug candidates for AD, including small molecules, natural products, and biologics which aim to prevent AD, slow its progression, or treat its cognitive and behavioral symptoms, and be eligible for FDA approval.
Projects can enter the program at ONE of the following stages:
- Early Stage – To optimize the agent’s potency, drug-like properties, specificity, pharmacological properties, and/or ADMET properties and undergo dose-range finding toxicology and initial IND-enabling safety toxicology,
- Late Stage – To advance development of candidates through all required IND-enabling toxicology studies, IND document preparation, and initial single dose, single ascending dose, or multiple ascending dose Phase I clinical testing
Award Budget: $1,500,000 direct costs per year
Project Period: 5 years for Early Stage projects; 4 years for Late Stage projects
Application deadlines: Several until October 5, 2027; next deadline is June 5, 2025
OVERVIEW OF 2025 NIH REQUIREMENTS
-
HSL Slides: Overview of 2025 NIH Requirements: Biosketch, SciENcv, and ORCID (1/8/2025)
These slides will be updated as more information is available from NIH.
TRAILBLAZER AWARD FOR NEW AND EARLY-STAGE INVESTIGATORS (R21 CLINICAL TRIAL OPTIONAL) (PA-25-169) Announced on January 8, 2025)
The Trailblazer Award is an opportunity for NIH-defined New and Early-Stage Investigators to pursue research programs that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data.
Application deadlines:
June 16, 2025
October 16, 2025
NIH FOCUSED TECHNOLOGY RESEARCH AND DEVELOPMENT (R01) (PA-25-203)
This program supports projects that focus solely on the development of technologies with potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to:
- laboratory instruments and other devices,
- algorithms and software,
- chemical reagents and processes,
- biological molecules or systems that have been modified by human intervention for use as research tool
Companion Funding Opportunity PAR-25-202, R21 Exploratory/Developmental Grants
Application Deadline: June 05, 2025
BASIC RESEARCH IN CANCER HEALTH DISPARITIES (R21 CLINICAL TRIAL NOT ALLOWED) (PAR-25-244)
This RFA invites grant applications from investigators interested in conducting basic research studies (including secondary data analyses) into the biological/genetic causes and mechanisms of cancer health disparities. There are several application deadlines until October 16, 2027; the next upcoming deadline is June 16, 2025.
TRANSLATIONAL RESEARCH IN MATERNAL AND PEDIATRIC PHARMACOLOGY AND THERAPEUTICS (R01 CLINICAL TRIAL OPTIONAL) (PAR-25-110)
The goal of this program is to support translational and clinical research that can (1) advance precision medicine in pregnant and lactating persons, and children, through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. Application deadlines are June 5, 2025; October 5, 2025; February 5, 2026
NOVANT-UNC FUNDING OPPORTUNITIES
Health Equity Research Presentation Travel Fund
Health Equity Research Training Awards
Applications accepted on an ongoing basis until all funds have been awarded, or until June 1, 2025.
HIGH IMPACT, INTERDISCIPLINARY SCIENCE IN NIDDK RESEARCH AREAS (RC2 CLINICAL TRIAL OPTIONAL) (PAR-25-277)
Application due dates: Several until October 15, 2027; next deadline June 03, 2025
Letters of Intent are due four weeks prior to the application due date
The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This RFA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases, including the promotion of health equity, within the mission of the NIDDK.
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.
The funding program supports efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
Budget: $499,000 (direct costs) per year
Project Period: Maximum 5 years.
Application deadlines: Several until October 5, 2027; next deadline is June 5, 2025
CUTTING-EDGE BASIC RESEARCH AWARDS (CEBRA) (R21 CLINICAL TRIAL OPTIONAL) (PAR-25-101)
The National Institute on Drug Abuse CEBRA is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA’s current portfolio that has the potential to transform SUD research. The proposed research should (1) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research, and /or (2) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.
Application Deadlines: Several until August 11, 2027; next deadline August 12, 2025
Letter of Intent Due Date(s): 30 days prior to the application due date.
INNOVATIVE MENTAL HEALTH SERVICES RESEARCH NOT INVOLVING CLINICAL TRIALS (R01 CLINICAL TRIALS NOT ALLOWED) (PAR-25-283)
The program supports innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research.
This RFA solicits research projects including, but not limited to the following: (a) research identifying mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development, (b) research that develops and tests new research tools, technologies, measures, or methods and statistical approaches to study these issues, and/or (c) research that integrates and analyzes large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches. Wherever possible, projects should leverage existing infrastructure and partnerships to accomplish these goals.
Application deadlines: Several until October 5, 2027; next deadline is June 5, 2025
Letter of Intent Due Date(s): 30 days prior to the application due date.